Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection

Thomas H. Price, Michael Boeckh, Ryan W. Harrison, Jeffrey McCullough, Paul M. Ness, Ronald G. Strauss, W. Garrett Nichols, Taye H. Hamza, Melissa M. Cushing, Karen E. King, Jo Anne H. Young, Eliot Williams, Janice McFarland, Jennifer Holter Chakrabarty, Steven R. Sloan, David Friedman, Samir Parekh, Bruce S. Sachais, Joseph E. Kiss, Susan F. Assmann

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (ResolvingInfection in NeutropeniawithGranulocytes), amulticenter randomizedcontrolled trial designed to address this question. Eligible subjects were those with neutropenia (absolute neutrophil count <500/μL) and proven/probable/presumed infection. Subjects were randomized to receive either (1) standard antimicrobial therapy or (2) standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. The primary end point was a composite of survival plus microbial response, at 42 days after randomization. Microbial response was determined by a blinded adjudication panel. Fiftysix subjects were randomized to the granulocyte arm and 58 to the control arm. Transfused subjects received a median of 5 transfusions. Mean transfusion dose was 54.9 × 109 granulocytes. Overall success rates were 42% and 43% for the granulocyte and control groups, respectively (P > .99), and 49% and 41%, respectively, for subjects who received their assigned treatments (P5.64). Success rates for granulocyte and control arms did not differ within any infection type. In a post hoc analysis, subjects who received an average dose per transfusion of ≥0.6×109 granulocytes per kilogram tended to have better outcomes than those receiving a lower dose. In conclusion, there was no overall effect of granulocyte transfusion on the primary outcome, but because enrollment was half that planned, power to detect a true beneficial effect was low. RING was registered at www.clinicaltrials.gov as #NCT00627393.

Original languageEnglish (US)
Article number645986
Pages (from-to)2153-2161
Number of pages9
Issue number18
StatePublished - Oct 29 2015

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection'. Together they form a unique fingerprint.

Cite this